My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Trials. 2009 Apr 7;10:20.

    Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD).

    Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Birket-Smith M.

    Liaison Psychiatry Unit, Psychiatric Centre Bispebjerg, Bispebjerg University Hospital, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark. baiba.hansen@gmail.com

    Abstract

    BACKGROUND: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome.

    METHODS: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures.

    DISCUSSION: This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor.

    TRIAL REGISTRATION: http://www.ClinicalTrials.gov. Identifier: NCT00140257.

    PMID: 19351383 [PubMed - indexed for MEDLINE]PMCID: PMC2674039Free PMC Article

    Supplemental Content

    Click here to read Click here to read

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    Write to the Help Desk